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Background: In mice, 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography/computed tomography
(PET/CT) lymphography enables detailed imaging of the lymphatic system and quantification of lymph node
function. If this applies to humans, it may improve staging of several malignancies. The aim of this study was to
elucidate whether foot skin depots of 18F-FDG make PET/CT imaging of the lower extremity lymphatic system
possible in man.
Findings: In four healthy volunteers, 18F-FDG depots (5 MBq in 0.1-mL isotonic saline) were injected intradermally
in one foot and subcutaneously in the other. Activity was measured in blood samples drawn simultaneously from
the great saphenous veins about 5 cm proximal to the ankle joints and a medial cubital vein before and every
minute for 15 min after depot injection. Immediately thereafter, a low-dose CT was performed from the ankles to
the pelvis followed by two consecutive PET scans of the same region.
Blood activity increased faster and to a greater extent in the great saphenous veins compared to the medial cubital
vein. PET/CT images showed activity in the superficial and deep veins of the lower extremities. No lymphatic
collectors or nodes were visualized.
Conclusion: Neither subcutaneous nor intradermal injection of 18F-FDG allows imaging of the lower extremity
lymphatic system in man.
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Background
Sentinel lymph node biopsy plays a key role in the staging
of malignant melanoma [1] and breast cancer [2]. Conven-
tionally, sentinel lymph nodes are localized by γ-camera
imaging after injection of 99mTc-labeled colloids. During
surgery, γ-probe counting and peritumoral blue dye injec-
tions guide sentinel lymph node resection [3]. However,
these techniques have received critique for being time-
consuming and having poor spatial resolution [4].
In a recent murine study, it was shown that intrader-
mal injection of 18F-fluorodeoxyglucose (18F-FDG) into
the tail skin enables detailed imaging of the lymphatic
system and quantification of lymph node function by* Correspondence: mads.radmer.jensen@regionh.dk
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in any medium, provided the original work is pmeans of combined positron-emission tomography/com-
puted tomography (PET/CT) [4]. In that study, it was
suggested that these findings might apply to man. If so,
it may improve the sentinel node technique through in-
creased spatial resolution, shorter acquisition times, and
improved anatomical localization.
However, in man, a likely path for the removal of intra-
dermal depots of 18F-FDG is through diffusion to systemic
capillaries. Activity in the blood from local veins will in-
crease faster and to a larger extent compared to that in
the blood from distant veins, and PET/CT imaging will
show activity in the local veins. Contrarily, if 18F-FDG is
drained primarily via the lymphatic system, a delay is
expected before 18F-FDG activity increases in venous
blood due to the transit time through the lymphatic sys-
tem, and PET/CT imaging is expected to visualize lymph-
atic collectors and lymph nodes.n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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foot skin depots of 18F-FDG allow for PET/CT lympho-
graphy of the lower extremities in man.
Ethical approval
The Science Ethics Committees for the Capital Region
of Denmark approved the study (protocol number: H-
2-2012-162). Written informed consent was obtained
from all subjects.
Subjects
Four subjects, three men and one woman, aged 33 to 62
years, participated as healthy volunteers. None of the
subjects suffered from any known disease or took any
medications. Small lower leg superficial venous ectasias
were allowed in the female subject.
18F-FDG-blood activity
Each subject was placed comfortably in supine position
on the scanner table. The great saphenous veins were
catheterized about 5 cm proximal to the ankle joints, and
a medial cubital vein was catheterized as well (20 gauge,
BD Venflon™ Pro, Becton Dickinson Infusion Therapy AB,
Helsingborg, Sweden).
Depots, each consisting of approximately 5-MBq 18F-
FDG in 0.1-mL isotonic saline, were injected into the
skin of the first toe interstitium on the dorsum of the
feet using a 1-mL syringe and a 27-gauge needle. On
one foot, the depot was injected subcutaneously and on
the other intradermally. Intradermal injection was veri-
fied by the elevation of a wheal at the injection site.
Careful aspiration before subcutaneous injection avoided
accidental intravenous injection. Different depot place-
ments were used to test whether this affects the drainage
route (veins vs. lymphatics).
Blood samples (2 mL/sample) were drawn simultan-
eously from each catheter before depot injection and
once every minute for 15 min thereafter. Samples were
transferred to pre-weighed plastic tubes, and sample ac-
tivity was counted in a well counter with decay correc-
tion (Wallac 1480 WizardW 3”, PerkinElmer, Waltham,
MA, USA). Finally, the samples were weighed (precision
1/100 g), and measured sample activity was corrected
for sample weight.
One subject deviated slightly from the described pro-
tocol on the following points: (1) catheterization of the
great saphenous veins only succeeded unilaterally (intra-
dermal depot); (2) depot activities were approximately 1
MBq/depot.
18F-FDG PET/CT imaging
Immediately following the last blood sample, approximately
20 min after depot injection, without moving the subject
on the scanner table, the PET/CT acquisition was started(Gemini TFW, Philips Healthcare, Best, The Netherlands).
A low-dose CT (20 mAs/slice) was performed from the an-
kles to the anterior superior iliac spine and followed by two
identical PET scans (1 min/bed position, axial coverage 18
cm, 50% overlap) of the same region. Protocol duration
was approximately 30 min. PET images were reconstructed
with the standard vendor-supplied ‘WholeBody’ protocol
including corrections for decay, scatter, and attenuation
and utilizing time-of-flight information.
Results
The results for each subject are shown in Figures 1, 2, 3,
and 4. Fused PET/CT images revealed 18F-FDG accumu-
lation corresponding to both superficial and deep veins
of the lower extremities in all subjects. Venous drainage
routes showed both intra- and interindividual variation.
Drainage pattern was not linked to depot placement.
Neither lymphatic collectors nor lymph nodes were vi-
sualized in any subject.
Time-activity curves showed that activity in great saphe-
nous vein blood increased faster and to a greater extent
compared to medial cubital vein blood in all subjects.
Great saphenous vein blood activity exhibited similar pat-
terns for intradermal and subcutaneous depots.
Discussion
In mice, 18F-FDG positron lymphography provides de-
tailed visualization of lymphatic collectors and lymph
nodes as well as quantification of lymph node function
after intradermal injection into the tail skin. However,
we show that this finding cannot be extrapolated to
humans as both intradermal and subcutaneous depots of
18F-FDG cause significant and immediate activity accu-
mulation in local venous blood. Both fused PET/CT im-
aging and time-activity curves showed this.
In man, transcapillary transport of glucose is governed
by diffusion through the interendothelial junctional space
[5]. A skin depot of 18F-FDG gives rise to a large local
concentration gradient between the interstitium and capil-
lary blood facilitating passive washout of the depot to the
systemic capillaries. Our results underline that important
physiological differences exist in 18F-FDG transport be-
tween mouse tail skin and human lower extremity skin.
One mechanism, which can explain the species difference,
is that the mouse tail skin is more tightly bound than the
skin on the human foot. This results in a higher hydro-
static pressure in the 18F-FDG depot in the mouse tail. It
is well described that a high interstitial pressure promotes
lymphatic drainage [6]. Another possible mechanism for
lymph node uptake of 18F-FDG in the study by Thorek
et al. is an inflammatory reaction to the co-injection of
isosulfan blue with 18F-FDG. Although not common, it is
well described that isosulfan blue injections in sentinel














Figure 2 Results for subject 2. For figure details, see legend of Figure 1. A 62-year-old male. Injected depot activity was 1 MBq in 0.1 mL/depot.
Catheterization was only possible on the left leg (i.d. depot). On the right lower leg (s.c. depot), 18F-FDG activity is visualized in a deep vein, while









Figure 1 Results for subject 1. A 58-year-old woman. 18F-FDG (5 MBq in 0.1-mL isotonic saline) was injected into the dorsal skin of each foot
subcutaneously (s.c.) on the right and intradermally (i.d.) on the left. (a) Axial low-dose CT of the distal lower leg. The great saphenous veins (GSV)
are indicated by arrows. Scan level corresponds to the horizontal dashed line in (d). (b) Axial PET superimposed on CT showing 18F-FDG activity
in a deep vein in the right lower leg. In the left lower leg, 18F-FDG activity is visible both superficially in the GSV and deeply in a posterior tibial
vein with a communicant vein. (c) Time-activity curve for blood samples from the medical cubital vein (MCV) and GSVs with either i.d. or s.c.
depot placement. Note the logarithmic scale on the y-axis due to large differences in measured activity. (d) Thick-slab maximum-intensity
-projection PET image of the lower body showing the activity distribution of 18F-FDG.













Figure 4 Results for subject 4. For figure details, see legend of Figure 1. A 33-year-old male. 18F-FDG activity is visualized in the great














Figure 3 Results for subject 3. For figure details, see legend of Figure 1. A 45-year-old male. On the right lower extremity (s.c. depot), 18F-FDG
activity is visualized in deep veins, while on the left (i.d. depot), in the great saphenous vein.
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cules such as human colloidal albumin to avoid capillary
washout and thus facilitate drainage by the lymphatic
system [8]. We suggest that a similar principle needs to be
applied in PET/CT lymphography in order to make the
method feasible in man.
Conclusion
Lower extremity PET/CT lymphography using 18F-FDG
skin depots in the feet is not possible in man due to sig-
nificant tracer washout to systemic capillaries.
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